US Pharma MarketingThe post First patient dosed in Daiichi Sankyo’s Phase I DS1025 study appeared first on Clinical Trials Arena.
First patient dosed in Daiichi Sankyo’s Phase I DS1025 study
Daiichi Sankyo has dosed the first patient in a Phase I clinical trial assessing DS1025 in adults with advanced or metastatic solid tumours who have experienced disease progression after at least one previous standard therapy. Enrolment is expected to reach up to 45 patients at multiple clinical sites in Asia and Europe. The trial will evaluate the pharmacokinetics, safety, tolerability, and preliminary efficacy of DS1025. Credit: PaeGAG / Shutterstock.com. Daiichi Sankyo has dosed the first patient in a Phase I clinical trial assessing DS1025 in adults with advanced or metastatic solid tumours who have experienced disease progression after at least…
Daiichi Sankyo has dosed the first patient in a Phase I clinical trial assessing DS1025 in adults with advanced or metastatic solid tumours who have experienced disease progression after at least one previous standard therapy.
Source: Clinical Trials Arena